Poland· PL-100299668
Erivedge
A vismodegib product containing vismodegibum, registered in Poland by Roche Registration GmbH. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Vismodegib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01XJ01 (vismodegib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Vismodegib · ATC L01XJ01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of vismodegib costs, country by country.
Normalised to the WHO defined daily dose (0.15 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Vismodegib · price per daily dose (0.15 g)
USD · FX 28 Sept 2026
- CH Switzerland$228.97
The record
At a glance
URPL (Poland)- Active substance
- Vismodegibum
- Manufacturer
- Roche Registration GmbH
- Country
- Poland (PL)
- ATC code
- L01XJ01
- ATC class
- Vismodegib
- Defined daily dose
- 0.15 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05902768001020
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
69 interactions on record for vismodegib.
Graded by severity as the source publishes them — 45 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Vismodegib · interactions on record
69 records
- 45 moderate
- 24 minor
Most severe, free to view
- QuinidineC01BA01moderate
- PropafenoneC01BC03moderate
- AmiodaroneC01BD01moderate
- DronedaroneC01BD07moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Vismodegib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandErivedgeParanova Oy
- NorwayErivedgeOrifarm AS
- SwitzerlandErivedge
- CzechiaERIVEDGERoche Registration GmbH, Grenzach-Wyhlen
- SpainERIVEDGE 150 MG CAPSULAS DURASRoche Registration Gmbh
- FranceERIVEDGE 150 mg, géluleROCHE REGISTRATION (ALLEMAGNE)
- United KingdomErivedge 150mg capsulesRoche Products Ltd
- IrelandErivedge 150 mg hard capsulesRoche Registration GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Erivedge
- Liechtenstein · Erivedge
- Norway · Erivedge
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ad91b0cc-c1c2-4ccd-a90c-13bec5ef7602 GET /v1/drugs/ad91b0cc-c1c2-4ccd-a90c-13bec5ef7602?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki twarde",
"source": "urpl",
"strength": "150 mg",
"packaging": "05902768001020 ¦ Rpz ¦ EU/1/13/848/001 ¦ 84826\n28 kaps.",
"substance": "Vismodegibum 150 mg",
"common_name": "Vismodegibum",
"pl_product_id": "100299668",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about vismodegib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.